MAP Pharmaceuticals Inc. submitted a new drug application to the U.S. Food and Drug Administration on Thursday for its orally inhaled migraine drug, branded LEVADEX, which had previously been delivered via intravenously.
The Mountain View-based company (NASDAQ:MAPP) alluded that the submission was coming in April.
No comments:
Post a Comment